Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary

May 12, 2020

London Stock Exchange GB Health Care Biotechnology earnings 35 min

Earnings Call Speaker Segments

Operator

operator
#1

Hello, everyone, and welcome to the conference call on Palatin Technologies' operating results for the third quarter of fiscal year 2020. Please note that this call is being recorded. Before we get into our remarks, I want to point out that any statements from Palatin that aren't historical facts could be forward-looking statements. Such statements rest on assumptions that may or may not turn out to be accurate, and because of various risks and uncertainties covered in the company's latest filings with the Securities and Exchange Commission, actual results could differ materially from what is anticipated. As you evaluate these forward-looking statements and Palatin's prospects, please weigh those risks and uncertainties carefully. I'll now hand the call over to today's host, Dr. Carl Spana, Palatin Technologies' President and Chief Executive Officer. Sir, please go ahead.

Carl Spana

executive
#2

Thanks. Good morning, everyone, and welcome to the call for Palatin Technologies' third quarter of fiscal year 2020. I'm Dr. Carl Spana, the CEO and President of Palatin's. Joining me today is Steve Wills, who serves as Palatin's Executive Vice President, Chief Financial Officer and Chief Operating Officer. During this call, we'll share financial and operating updates, and that includes how the COVID-19 pandemic has affected us. We truly hope that you and your families remain safe and healthy as you cope with the life-altering changes the COVID-19 pandemic has brought about. As with many of you, some members of the extended Palatin family are working on the frontlines — dozens are caring for patients. To them, we are eternally grateful. We applaud their dedication and pray for their safety. Today, Steve will give a financial update as well as an update on AMAG's divestiture of Vyleesi. My update will center on the progress of our exciting development programs. Now I'm going to hand the call over to Steve.

Steve Wills

executive
#3

Thanks, Carl, and good morning to everybody. As Carl said, I’ll cover the Vyleesi program update and then walk through the financial results for the quarter that closed on March 31, 2020. On Vyleesi—an approved therapy for Hypoactive Sexual Desire Disorder, or HSDD, in premenopausal women—it is the first as-needed treatment cleared for premenopausal women who have acquired, generalized HSDD. Our North American licensee, AMAG Pharmaceuticals, rolled Vyleesi out across the U.S. in September 2019 via selected specialty pharmacies, using its established women’s health sales team. In January 2020, AMAG said that following a strategic review it would begin the process of divesting Vyleesi. In May 2020, AMAG indicated it is negotiating the divestiture of Vyleesi and will give an update in the coming few months. Palatin keeps a close watch on AMAG’s divestiture process for Vyleesi, along with AMAG’s obligations under the license agreement between Vyleesi and Palatin. Although Vyleesi sales have been negatively impacted by the COVID-19 pandemic, the company thinks AMAG’s divestiture process has hurt Vyleesi’s sales as well. Palatin stands ready to take suitable steps to safeguard its rights as licensor of Vyleesi and the substantial value of the Vyleesi program.

Steve Wills

executive
#4

Palatin is still in talks about Vyleesi partnerships covering markets beyond the areas it currently licenses—North America, China, and Korea—and expects to sign several deals in the back half of this year as well as in calendar 2021. Now turning to the financial results for the third quarter of fiscal year 2020. On revenue: for the quarters that closed on March 31, 2020 and 2019, no revenue was recorded. Because Vyleesi is at an early commercial stage and because of AMAG's sales and marketing approach—which includes no charge for a patient's first Vyleesi prescription—AMAG had not produced positive net sales through March 31, 2020. As a result, Palatin received no royalties in that period. On operating expenses: total operating expenses for the quarter that ended March 31, 2020, came to $5.7 million, versus $5.8 million in the same quarter of 2019. That decline in operating expenses stemmed mainly from an overall cut in research and development expenses, partly offset by a modest rise in general and administrative expenses. Other income and expense, net—total other income, net, was roughly $331,000 for the quarter that ended March 31, 2020, against total other income, net, of roughly $35,000 for the quarter that ended March 31, 2019. The main factor behind that gap is higher investment income.

Steve Wills

executive
#5

On the net loss side, Palatin posted a loss of $5.4 million, or $0.02 per basic and diluted share, for the quarter that ended March 31, 2020. That compares with a net loss of $5.7 million, or $0.03 per basic and diluted share, in the same period of 2019. The gap in financial results between the 3 months ended March 31, 2020 and 2019 came mainly from the rise in other income net. Turning to cash position, Palatin's cash and cash equivalents stood at $88.9 million as of March 31, 2020, versus $91.5 million at December 31, 2019, and versus cash, cash equivalents and accounts receivable of $103.8 million at June 30, 2019. Management's view is that existing capital resources will be sufficient to fund the company's planned operations through at least March 31, 2022. Carl?

Carl Spana

executive
#6

Thank you, Steve. For the operational update, I'll begin by discussing how the COVID-19 pandemic has affected us. The safety of our employees, our patients and health care partners has been our main priority. Early in March we put a work-from-home policy in place, and it is still in effect today. Luckily, the majority of our key research and development partners are still operating. Through teleconferences and a range of online meeting platforms, we have been able to keep advancing our programs effectively. If economic activities partially reopen by mid-2020, we expect the pandemic's impact on our operations to be limited. That said, we recognize that even as activities resume, business activity could face additional disruptions if the virus resurges, and we will be ready for that scenario. Palatin's main scientific focus is the melanocortin system, which plays a part in regulating energy balance, including food intake, sexual function and the resolution of inflammatory responses. Our first successful program involving the melanocortin system was built on the role that this system plays in regulating sexual function. That research led to the discovery of Vyleesi and, ultimately, to its approval by the Food and Drug Administration as a treatment for premenopausal women who suffer with Hypoactive Sexual Desire Disorder.

Carl Spana

executive
#7

Lately, our research has focused on creating drugs that harness the melanocortin system's capacity to settle or dampen inflammation. We've produced several drug candidates, and in preclinical models these have shown the potential to resolve a range of inflammatory disease conditions. Work done by our team and by others has demonstrated that when melanocortin drugs act on immune cells, pro-inflammatory processes get resolved. Such pro-resolution effects include helping immune cells shift from an inflammatory state to a regulatory one; blocking production of pro-inflammatory cytokines, for example TNF-alpha, IL-6 and others; and raising levels of anti-inflammatory cytokines like IL-10. Beyond that, the melanocortin system helps lessen the fibrotic response that accompanies many inflammatory diseases. Fibrosis stemming from inflammatory disease leaves patients with long-term negative health consequences. Because the melanocortin system takes multiple actions to regulate the overactive immune response seen in many inflammatory diseases, it is an exciting target for novel drugs. So we believe melanocortin drugs aimed at the immune system will be broadly useful for treating inflammatory diseases. We've developed clinical stage drug candidates for ocular diseases including dry eye disease, noninfectious uveitis and retinal diseases.

Carl Spana

executive
#8

In addition, we have a cabinet of drugs at the clinical stage for GI conditions like ulcerative colitis. PL-9643, our first-line important immune-system target, launched a Phase II placebo-controlled trial in dry eye disease with an eye drop formulation in January 2020. Keratoconjunctivitis sicca, commonly called dry eye disease, impacts the eye's cornea and conjunctiva, causing irritation, redness, pain, and blurred vision. The problems vary, and we think that by activating the melanocortin system locally, PL-9643 will lower the inflammation behind many facets of dry eye disease. The initial patient group was enrolled before the COVID-19 pandemic, and those patients have kept receiving treatment, and we expect they will complete their study treatment in May 2020. Right now, enrollment in the study is paused. Following talks with our contract research organization that runs the study, we believe a significant number of patients are waiting to enroll, and we anticipate starting to enroll new patients in June. That will let us finish the study and have the data in the fourth quarter of 2020. If we can restart enrollment in June, the COVID-19 pandemic's impact on the study will have been limited.

Carl Spana

executive
#9

That successful trial is going to give us the data we need to move PL-9643 ophthalmic solution forward into the pivotal Phase III studies, and those will kick off during the first half of 2021. When you look at dry eye disease treatments, the market there is a meaningful commercial opportunity — more than $2 billion in yearly sales, and it keeps growing as patient demographics shift. We think PL-9643's potential efficacy, together with its favorable tolerability and safety, should permit substantial penetration of the dry eye market. For our retinal disease indication and noninfectious uveitis, the clinical trials are now set to begin in the first half and the second half of 2021, respectively. That works out to a 2- to 3-quarter delay, and the cause is the impact of the COVID-19 pandemic. We're putting that extra time to use deepening our scientific understanding of the melanocortin system in ocular inflammation. Beyond the ocular pipeline programs, we've developed an oral colon release formulation of PL-8177 for treating ulcerative colitis as well as other inflammatory bowel diseases. We have finished 2 Phase I clinical trials of PL-8177. The first one was a combined single ascending and multiple ascending dose study evaluating the systemic safety of PL-8177 given subcutaneously. The second trial assessed the pharmacokinetics and safety of the oral colon delivery formulation of PL-8177.

Carl Spana

executive
#10

We intend to put money into a Phase II placebo-controlled proof-of-principles clinical trial involving patients with ulcerative colitis. That trial is set to begin during the first half of 2021, with data readout expected in the second half of 2022. That amounts to a delay of roughly 2 quarters stemming from the pandemic. Drawing on the research we have done on the natriuretic peptide system, our drug canvas PL-3994, a natriuretic peptide receptor-A agonist, will be assessed in a Phase IIa clinical study among heart failure patients with preserved ejection fraction. The planned study is a collaboration with 2 major academic medical centers and is supported by an American Heart Association brand. Enrollment of patients in that study is now expected to begin in the second half of calendar year 2020. Fortunately, our preclinical research activities, along with the toxicology, manufacturing and other drug development work needed to file investigational new drug applications with the Food and Drug Administration, have been able to proceed on schedule, with only limited impact from the COVID-19 pandemic. Additional information about our programs is available on our website, www.palatin.com. Given the extreme global uncertainty brought about by the COVID-19 pandemic, executive management and the Board of Directors moved quickly to adjust our business operations. We acted immediately to ensure the safety of our employees, patients and health care partners.

Carl Spana

executive
#11

We've implemented operational procedures that let our staff stay very productive. Continuing to move our development programs forward, along with a solid cash position, means Palatin can come out of the pandemic in a strong place. Even so, we'll stay vigilant and have plans ready in case the virus resurfaces. We expect AMAG's divestiture of Vyleesi to happen by the close of the second quarter of calendar 2020, and we're taking the right steps to protect our rights under the Vyleesi North American license agreement so that Vyleesi's value stays intact. We have a robust pipeline of novel plant clinical drug candidates, and we're staying focused on advancing them, continuing to push their development forward, which we anticipate will speed up as business activities start to normalize. To wrap up, I want to thank the Palatin team and all our development partners for how quickly they adjusted to our new working environment and for their ongoing dedication to advancing our novel drug candidates. Thank you. We'll now open the call for questions.

Operator

operator
#12

<<operator_script>> Our first question today comes from John Newman of Canaccord.

John Newman

analyst
#13

I just have a question about the Vyleesi divestiture. I believe you mentioned in your prepared remarks that you expect the divestiture to be finalized within the next several months. But you also spoke about protecting the value of that asset. Would you say that, as a company, you have concern regarding the timing of the divestiture? Or is your concern more about the terms of the divestiture?

Steve Wills

executive
#14

Steve here, John — thanks for asking. It's a bit of both, really. As I said, we think the Vyleesi program has taken some damage. That's simply inherent — any divestiture process will naturally bring that about. Our license agreement contains fairly standard provisions requiring reasonable commercial efforts on the program. And AMAG just hasn't been in a position to do that while the divestiture has been underway. As I think you know, they already carried out one reduction early in the first quarter of 2020, and on their conference call yesterday they said they're making another significant reduction. So we're focused on two things. We do have some — we think we hold some reasonable influence here. Our aim is to ensure whoever takes over Vyleesi next has both the capability and the commitment. Beyond that, as I mentioned, we're watching the process closely, and we stand ready to see that our rights are safeguarded and that any damages tied to the Vyleesi program get resolved.

John Newman

analyst
#15

I'm also curious whether there's any chance you might aim to get that asset back through the process you're looking at. And if that's the case, would you rather commercialize it yourselves, or would you also look into the possibility of licensing the asset again?

Steve Wills

executive
#16

Alright. I’ll focus on Vyleesi, and once I’ve finished my answer, Carl can add any additional perspective. There is a possible path through which Palatin could regain the rights to Vyleesi. We’re very aware of that. Because of certain confidentiality considerations, Carl and I really aren’t able to elaborate on that. But we are making sure that if an event of that kind occurs, we’re as ready as we can be. As for the second part of your question, John, there isn’t — we’re not in a position to say that if we got it back, we would definitely commit ourselves to the female health care franchise landscape, or that we would license. More than likely it would be some combination of those two paths. At present, we don’t have that kind of infrastructure in place. Frankly, we’ve moved in a different direction from female health care, as Carl has described very thoroughly with respect to our anti-inflammatory and autoimmune programs. But we’re going to make sure that Vyleesi has the best chance of holding nominal value for shareholders. So if that best chance means it sits in Palatin’s hands for a period of time, that period could be a year, or it could be longer.

Steve Wills

executive
#17

But we’d set it up in a way that gives us flexibility and optionality, so if it made sense, would we consider relicensing it? Absolutely.

Operator

operator
#18

Our next question comes from Joe Pantginis at H.C. Wainwright.

Joe Pantginis

analyst
#19

Steve, please go ahead. And Carl, I’m glad to hear you’re doing well further to your earlier remarks. So your statement that the divestiture process has also had a negative effect on sales — that might be a bit of a stretch at this point, or it may put you on the spot. But my understanding is that AMAG, under the contract, was essentially required to keep acting in good faith to preserve and grow the franchise. That said, are we beginning to enter — or have we already entered — the legal arena regarding a possible breach of contract?

Carl Spana

executive
#20

Joe, it's Carl here. Steve may also want to chime in. No, we have not. Our preferred scenario would involve Vyleesi being divested in whatever way serves the product best, with no need for legal action. Still, I think it's important to recognize that we see substantial value in Vyleesi, and we've held conversations about that value across the years. That value is something we intend to defend. In our view, it is a highly valuable asset. The reason we've issued the statements — including legal statements — that we have is to make certain shareholders understand clearly that we believe value exists here. And if necessary, we will defend our rights so that Vyleesi ends up in a home with a company committed to realizing that value. Steve, I don't know whether you'd like to add anything more.

Steve Wills

executive
#21

No, I'll stick with what you said, Carl. You put it very well. So I'm fine with your statement.

Joe Pantginis

analyst
#22

Great, that's really useful. Thanks for making it clear. The second thing I wanted to ask about is where you already have partnerships and markets you can reach in the relatively near term. I just wanted to check, for instance, whether there are any new timelines for approval in China and Korea, and for the partnerships you currently have outside the U.S. I understand some potential short-term PK bridging studies were needed. I wanted to ask about where those stand.

Carl Spana

executive
#23

Sure. I would say that we are getting ready and collaborating with our partners in Korea and China alike. They have been through thorough conversations with regulators regarding what steps they must take. And really, at this point we are in the midst of supplying drug product and so forth so that they can begin their studies. The impact is unknown to us. We have not yet held any direct talks with them. What effect, if any, the COVID-19 pandemic might have on their capacity to carry on with those studies or to finish them according to their own schedules. I believe it would be fair to state that some slippage in their time lines is possible. But what I observe, and I feel quite at ease about, is that the partners in both China and Korea have shown remarkable dedication to this product. We are in touch with some — several times weekly — and have truly collaborated quite closely with them, and they do seem to be strongly committed to the product. And I am certain that over the coming quarter or so, we will gain a clearer picture as these trials get under way. Whether — or what effect the pandemic would have on them and how that could influence an eventual time line.

Operator

operator
#24

And next up, from Ladenburg Thalmann, we'll hear from Michael Higgins.

Michael Higgins

analyst
#25

Let me take a step back and focus on Vyleesi for a moment. Could you give us an update on the communications you’re having with AMAG? I’m not sure whether it’s properly called a joint venture — whatever the exact arrangement with them is on the marketing side. But under that shared agreement you have, are you a party to the conversations they’re holding? Do you know who is generating the inbound interest, what those discussions look like, how much they’re offering — that sort of thing? How much detail do you have, I suppose, into their negotiating?

Steve Wills

executive
#26

Yes. Thanks for that question, Michael. This is Steve, and I’ll handle the first part. Because of confidentiality factors, we really can’t go into much detail beyond telling you that we’re the licensor. Anyone who would be interested in taking over the rights from AMAG would inherently and variably have discussions with us. Again, due to confidentiality factors, we’re not at liberty to go into any type of granularity, but we are involved with the process. And we’re working with AMAG. As Carl mentioned, we want to make sure as best we can that the next home of -- with Vyleesi is the best home. But in the same sense, we want to protect our rights and -- in any deterioration of value in the Vyleesi program. But we are friendly with AMAG at this stage and involved with the divestiture process.

Michael Higgins

analyst
#27

Just to follow up on that, and I appreciate you can't give much detail on the situation, but I'm trying to understand it from the outside here. Given your contractual obligations and theirs, how much are you able to prevent those rights from being sold, if it's something that's just too small in your estimation? Can you put your foot down on it? Or is it simply that they have, let's say, a 51%-49% situation where they get the final say?

Steve Wills

executive
#28

Steve here again, Mike — I just can't provide that kind of granular detail in my response. We're collaborating with AMAG to ensure the arrangement is as favorable as possible for everyone involved. That's really all the detail I'm able to offer at this point. So I hope you understand the confidentiality considerations surrounding matters like this. As AMAG said yesterday during their call, they'll be providing an update within the coming several months. And we think that update will be very — it will be specific about the next steps with Vyleesi. And as you remember, it wasn't only the Vyleesi program. There were 2 programs that AMAG — there are 2 commercial programs tied to the female health care franchises that they made the strategic decision to divest.

Michael Higgins

analyst
#29

Yes. I'd figure that would essentially reverse things — helping certain cases while perhaps pushing others back — but let me continue. Thanks for your feedback. I realize you're unable to reveal everything we might wish to hear about it. So, a question about the dry eye program. You said you hope to get the 9643 Phase II going again in June. What makes you confident it can be restarted in June rather than being pushed to the summer, later in the summer, or possibly the fall?

Carl Spana

executive
#30

I'll take that question. The CRO we're working with is Ora, and this is their specialty — they're highly specialized. In fact, we've already had the first cohort of patients, and 90% of them kept coming back each month. They managed to revise their processes so exam rooms and the like were cleaned properly. And patients returned. They have a big pool of patients and extensive outreach. So when we reach out to them and they reach out to their patients, more than enough patients have shown a desire and interest in enrolling in this study. Of course, external factors can affect that. For instance, the states where these sites are — mostly in the Northeast — where they might come in, they shut down and say you can't do it. But I think assuming there's a groundswell, I guess, among the general population in most states now saying it's time to get back to business, I think that by June, we feel comfortable that enrollment will be able to open up, or has developed and put in place systems that will ensure patients' safety, making sure the appropriate PPE gear is in place and that patients are spaced appropriately. So we've been working very closely with them to make sure this study can begin its enrollment as quickly as possible.

Carl Spana

executive
#31

Naturally, we’re operating in a highly unpredictable environment. At any moment, clearly, a resurgence could occur, and it’s possible we’d need to close things down once more. Should that happen, then clearly we would take whatever actions are required to protect patient safety as well as the safety of the health care workers running the study. But assuming we’ll see a relaxation of — or fewer limits on people’s movement, the capacity to wear face masks, social distancing across most states, we ought to be able to restart the study safely. So here’s what I can say: we collaborated very intensively with Ora. In my view, they’ve performed exceptionally well in guiding the patients we have right now through. I was surprised that — I mean, it wasn’t a big cohort. It’s roughly 20-some-odd patients, yet the great majority of them, 90%-plus, have remained in the study. They’ve shown up for their monthly visits and their monthly analyses, and they will finish this month. So with that guidance, we need to provide you with our view regarding what the impact is likely to be.

Carl Spana

executive
#32

June is the date we’re aiming for. And right now, assuming nothing external happens or there’s no government change on something, we expect a June start. If that happens, the patient study will be finished and we’ll have the data in the fourth quarter, which is really on schedule. So the impact could be very minimal. But — and so that’s the guidance and what we have. Of course, the risk is, of course, nobody knows what’s happening with this virus, and if it resurges, then we’ll handle it appropriately.

Michael Higgins

analyst
#33

Okay, that's useful. Yeah, my sense is that in a downturn, Phase I studies don't struggle much with enrollment or retaining patients. I'd say regulations are the bigger concern. It sounds as though you now have clarity regarding those sites and those states where they're able to launch in June. Is that accurate?

Carl Spana

executive
#34

Yes. Absolutely, we have. And predominantly — 2 of the sites are Ora sites. So they're under very tight control. There are very limited staff there. Only necessary staff is there. And look, they've instituted the appropriate — in guidance with the CDC and other government agencies, instituted the appropriate steps. And keep in mind, listen, the health care — I'm going to give you a general statement, the hospitals and the health care practices in this country are going to have to start to get back to work very soon. They're losing tremendous amounts of money. And they're going to need to get back to work. I can tell you from a personal experience in the hospitals that I have family members that work at, they are preparing to open up and begin doing surgeries. I know I have family members that are surgeons that are beginning to operate. So this is going to change. We have to get on with life, and we have to get on with treating patients. There are patients out there that have disease conditions that have been put on hold so — health care is going to open up again and health care treatment and practicing is going to open up again.

Carl Spana

executive
#35

My view is that this can be done safely. I'm certain we can do it safely. Throughout this pandemic, as we've demonstrated the whole time, we have been treating these patients. So my confidence is high that we will need it. But I always have to add the caveat, and all of you need to keep at the back of your minds that our knowledge of how this virus operates and how it spreads is only partial. We don't know everything. At any point it can make a resurgence, that will cause another quarantine in place.

Michael Higgins

analyst
#36

Let me squeeze in one last question, about Vyleesi's digital marketing and brand awareness. Is that still going on? Is AMAG continuing to do that? You might not be able to put people on the ground, but those digital ads can be quite efficient. Do you have any feedback for us on them?

Steve Wills

executive
#37

Hey Steve, it's Michael. In line with the cuts they've made — and even setting aside the people they have on the ground — there has also been a pullback when it comes to DTC and those kinds of things on the Vyleesi program.

Carl Spana

executive
#38

They have resumed their effort and their spending.

Operator

operator
#39

And now I’ll hand the call back to Dr. Spana for any closing remarks.

Carl Spana

executive
#40

Well, first off, I want to thank everybody for joining us on this call. Our analysts and the questions they raised definitely help us make our communications clearer for investors who are either listening right now or who will hear the call at some point down the road. I can just tell all of you, these are unprecedented times, so please stay safe. Keep your distance socially. Wash those hands. Keep your hands away from your face. These measures work. We truly want every one of you to stay safe, and we hope business activity can return to normal before long. Obviously, we look forward to giving you updates. How we do that going forward is certainly going to look different. Once we start getting some clarity on Vyleesi and a few of the exciting earlier-stage projects we have underway, we will certainly be holding virtual non-deal road shows. Steve and I both will be out there talking about the company. We think we're in an extremely exciting spot as we make this transition. The Vyleesi story is going to unfold. I'm optimistic, and I believe Steve is too, that it will turn out favorably. And it will land with someone who will back it.

Carl Spana

executive
#41

This is a strong product with a strong label, and it delivers results. From the women we've spoken with, we know they're fans of it. They're going to use it. And I'm hopeful that it can find a home and pick its launch activities back up. So I want to thank all of you. Stay safe. We'll speak with you soon. Bye-bye.

Operator

operator
#42

That brings us to the end of today’s call. Once more, thanks to everyone for being with us.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.